← Back to patent-cliff list
RS-5614
Tier C — Watch / tradeRS-5614
Renascience Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PAI-1
Indications (approved)：Chronic myeloid leukaemia, Non-small cell lung cancer, Melanoma, Interstitial lung disease, COVID-19, Angiosarcoma
Regional status
US
Phase II
2021-01-08
EU
-
China
-
Japan
Phase III
2024-04-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RS-5614?
Approved indications include: Chronic myeloid leukaemia, Non-small cell lung cancer, Melanoma, Interstitial lung disease, COVID-19, Angiosarcoma.
When does the RS-5614 patent expire?
No public expiry year is available for RS-5614 yet; this page updates once verified.
How do I get a quote for RS-5614 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01